We developed a new genetically engineered model of GBM based on chronic, autocrine PDGF-A stimulation of overexpressed PDGFRα in the context of loss of p53, genetic events that are clinically supported by the cancer genome atlas data (Cancer Genome Atlas Research Network, 2008; Verhaak et al, 2010; Brennan et al, 2013). Here, TP53 is linked to cancer.